ThromboGenics Announces Publication of Paper in Journal Cell
News Mar 04, 2013
ThromboGenics NV has announced the publication of a paper in the prestigious journal Cell, highlighting the potential of TB-403 to improve the treatment of medulloblastoma, the most common brain tumor in children.
The Cell publication highlights for the first time a new mechanism of action showing that PlGF plays a vital role in the brain and that its expression is required for the growth and spread of medulloblastoma.
The novel positive findings in this paper provide evidence that could warrant further development of TB-403 as one of the first targeted therapies to treat this childhood cancer. TB-403 is a monoclonal antibody against placental growth factor (PlGF).
PIGF is a naturally occurring protein that belongs to the family of vascular endothelial growth factors (VEGF) that promote the formation of blood vessels.
TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB), where the therapeutic potential of anti-PlGF agents to treat cancer was first developed by Prof. Peter Carmeliet at the University of Leuven, Belgium.
This Cell paper is reporting the findings of new pre-clinical research performed at the Massachusetts General Hospital in Harvard (Boston), in collaboration with the team of Prof Peter Carmeliet.
With an emerging ophthalmologic franchise, Thrombogenics is also evaluating the role of TB-403 for ophthalmic indications.
Cellular Valve Structure Opens Up Potential Novel TherapiesNews
Biochemists have determined the detailed structure of a volume-regulated chloride channel. This cellular valve is activated in response to swelling to prevent the cell from bursting. The protein also plays an important role in the uptake of chemotherapeutics and the release of neurotransmitters after a stroke. The controlled regulation of its activity thus opens up a promising strategy for novel therapies.READ MORE
Stem Cell Signaling Drives Mammary Gland DevelopmentNews
New research illuminates the biology of breast tissue development and may pave the way to new strategies for diagnosing or even treating cancer.READ MORE
Inflammatory Bowel Disease Linked with Common Bacterial Gut ToxinNews
New research has uncovered a surprise link between a common bacterial toxin found in the gut and inflammatory bowel disease (IBD). It shows that breakdown products from the toxin seem to trigger gut inflammation that is characteristic of IBD.READ MORE